Leukemia

News, features, and commentary about cancer-related issues

Study suggests "watch and wait" should remain standard of care

News, features, and commentary about cancer-related issues

A case for monitoring global longitudinal strain despite normal LVEF

News, features, and commentary about cancer-related issues

One young patient achieved molecular remission within 28 days of infusion

All patients had progressed on BTK inhibitors and most had failed venetoclax

News, features, and commentary about cancer-related issues

5-year OS increased to 100% in standard-risk ALL patients at a Tijuana hospital

5-year PFS rate represented "significant improvement" over historical 2-year rate, authors say

But trial detects "meaningful benefit" when it comes to relapse, editorialists say

Magnitude of the risk is "striking," editorialists say

Median OS improved from 15 months to nearly 32 months with quizartinib

Low incidence of relapse after treatment "remarkable," researchers say